{"id":"W3164115667","doi":"10.1016/j.ejca.2021.03.029","title":"Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Samsung; Genentech; Merck Sharp and Dohme; Eisai; MacroGenics; Puma Biotechnology; PharmaMar; Celgene; Jounce Therapeutics; Mylan; Genomic Health; Ipsen; Syndax Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Olaparib; Metastatic breast cancer; Internal medicine; Oncology; Taxane; Nausea; BRCA mutation; Breast cancer; Interim analysis; Adverse effect; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01040806,0.001670652,0.002624386,0.0004227343,0.0005285882,0.002104501,0.00129367,0.001710984,0.003574411],"category_scores_gemma":[0.004767913,0.0006233616,0.003312257,0.000635085,0.0016553,0.001249288,0.0006738728,0.003419505,0.001004697],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001576558,"about_ca_system_score_gemma":0.002342781,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000676011,"about_ca_topic_score_gemma":0.000893075,"domain_scores_codex":[0.9968917,0.002186203,0.0001163467,0.0002646372,0.0002058616,0.0003353633],"domain_scores_gemma":[0.9957634,0.001334353,0.00117106,0.0005798285,0.0003196584,0.0008316863],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9426835,0.01503681,0.006539502,0.0004688298,0.002354862,0.0001144995,0.0001284934,0.003825909,0.004307181,0.0001955013,0.00297814,0.02136675],"study_design_scores_gemma":[0.665967,0.3040927,0.01846289,0.00008388653,0.001877823,0.0002819942,0.00007000418,0.003710132,0.002106145,0.0004676718,0.002818314,0.00006143875],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819349,0.004300169,0.002050584,0.00100537,0.0001450706,0.003313414,0.004439795,0.0001963797,0.002614316],"genre_scores_gemma":[0.9848668,0.001213819,0.002696855,0.0008509791,0.0002246623,0.003739302,0.005113184,0.00005540271,0.001238942],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01040806,"threshold_uncertainty_score":0.05504376,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04795153637465649,"score_gpt":0.4481784648935772,"score_spread":0.4002269285189207,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}